GlassScriptPhysician profile
Manisha Mittal
NPI 1154627776
$6,749.01
in general payments reported to CMS, 2019-2025
29 companies · $790 in 2025
The $790 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $439 · 2021: $1,326 · 2022: $1,571 · 2023: $1,031 · 2024: $1,179 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.74 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,117.30 | 2020-2025 | Benlysta, Bexsero, Pediarix |
| Horizon Therapeutics Plc | $908.62 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $770.47 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $756.67 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $681.66 | 2019-2025 | Krystexxa, Uplizna, Prolia |
| E.R. Squibb & Sons, L.L.C. | $524.32 | 2019-2025 | Orencia |
| Abbvie INC. | $300.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.14 | 2019-2023 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.72 | 2021-2025 | Xifaxan |
| Ucb, INC. | $194.43 | 2020-2024 | Cimzia |
| Intercept Pharmaceuticals, INC. | $170.27 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $127.86 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $109.86 | 2019-2025 | |
| Pfizer INC. | $90.90 | 2019-2022 | |
| Ardelyx, INC. | $89.24 | 2024-2025 | Ibsrela |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $67.45 | 2024 | Idacio |
| Organon LLC | $50.17 | 2025 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $41.63 | 2022 | |
| Merck Sharp & Dohme LLC | $37.61 | 2019 | |
| Aurinia Pharma U.S., INC. | $37.30 | 2021-2023 | Lupkynis |
| Genentech USA, INC. | $29.00 | 2025 | Gazyva |
| Novo Nordisk INC | $22.63 | 2023 | |
| Celgene Corporation | $20.73 | 2022 | |
| Daiichi Sankyo INC. | $19.88 | 2020 | |
| Bioventus LLC | $19.73 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $17.72 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.03 | 2019 | |
| Lilly USA, LLC | $16.10 | 2023 | Taltz |
| Redhill Biopharma INC. | $15.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.